Biopolym. Cell. 2014; 30(1):77-79.
http://dx.doi.org/10.7124/bc.000883
Short Communications
Growth suppression activity of bradykinin antagonists in glioma cells
1Avdieiev S. S., 2Gera L., 2Hodges R., 3Vassetzky Y. S., 1Kavsan V. M.
  1. State Key Laboratory of Molecular and Cellular Biology
    Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680
  2. University of Colorado Denver
    Anschutz Medical Campus, Aurora, Colorado, USA, 80202
  3. CNRS UMR 8126, Universit Paris-Sud 11, Institut Gustave Roussy
    114, rue Edouard Vaillant, Villejuif, France, 94805

Abstract

The present study was Aimed at analyzing the effect of bradykinin (BK) antagonists on proliferation of the human glioblastoma cells U373. Methods. MTT-based cell proliferation assay. Results. BKM-570 revealed a significant antiproliferative activity in the U373 cells with LC50 3,8 M. Conclusions. The antiproliferative properties of BK antagonists were shown in vitro using the glioma cells. Further investigations of the molecular mechanisms of their action and pre-clinical studies on animal models are needed for the evaluation of these compounds as new anti-cancer drugs.
Keywords: bradykinin antagonists, glioma cells, antiproliferative activity
Full text: (PDF, in English)

References

[1] Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A, Maeda H. Enhanced vascular permeability in solid tumors involving peroxynitrite and matrix metalloproteases. Jpn J Cancer Res. 2001; 92(4):439–51.
[2] Wu J, Akaike T, Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor and a nitric oxide scavenger. Cancer Res. 1998; 58 (1):159–65.
[3] Gera L, Chan DC, Helfrich B, Bunn PA, York EJ, Stewart JM. Bradykinin-related compounds having anticancer activity in vivo superior to cisplatin and SU5416. Peptides 2000. Proc. of the 26th Eur. Peptide Symp. Eds J. Martinez, J.-A. Fehrentz. Paris: EDK Publ., 2001; 637–8.
[4] Montana V, Sontheimer H. Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci. 2011; 31(13): 4858–67.
[5] Stewart JM, Gera L, Chan DC, Bunn PA, York EJ, Simkeviciene V, Helfrich B. Bradykinin-related compounds as new drugs for cancer and inflammation. Can J Physiol Pharmacol. 2002; 80 (2):275–80.
[6] Gera L, Chan DC, Simkeviciene V, Bunn PA, Stewart JM. N(Fluorenyl-9-methoxycarbonyl)amino acid amide derivatives as a newclass of anti-cancer agents. Adv Exp Med Biol. 2009; 611: 465–6.
[7] Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wiggler MH, Downes CP, Tonks NK. The lipid phosphatase activity of PTEN is critical for its tumorsupressor function. Proc Natl Acad Sci USA. 1998; 95(23):13513–8.